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http://dx.doi.org/10.1016/j.ccr.2013.02.025SUMMARYThe identification and targeted therapy of cells involved in hepatocellular carcinoma (HCC) recurrence remain
challenging. Here, we generated a monoclonal antibody against recurrent HCC, 1B50-1, that bound the iso-
form 5 of the a2d1 subunit of voltage-gated calcium channels and identified a subset of tumor-initiating cells
(TICs) with stem cell-like properties. A surgical margin with cells detected by 1B50-1 predicted rapid recur-
rence. Furthermore, 1B50-1 had a therapeutic effect on HCC engraftments by eliminating TICs. Finally, a2d1
knockdown reduced self-renewal and tumor formation capacities and induced apoptosis of TICs, whereas its
overexpression led to enhanced sphere formation, which is regulated by calcium influx. Thus, a2d1 is a func-
tional liver TIC marker, and its inhibitors may serve as potential anti-HCC drugs.INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the deadliest cancers,
mainly due to its high rate of recurrence, which can be as high as
70% following conventional treatments such as surgical resec-
tion, arterial embolization, and radiofrequency ablation (Llovet
and Bruix, 2008; Xu et al., 2010). The cellular origin of HCC recur-
rence remains poorly understood, and, as yet, no specific treat-
ment strategy has been developed that focuses on HCC
recurrence.
HCC, like other cancer types, is composed of phenotypically
and functionally diverse cell types (Shackleton et al., 2009; Vis-
vader, 2011). It is hypothesized that a rare subset of cancer cells,Significance
This study identified a population of cells with the TIC propert
margins using the monoclonal antibody, 1B50-1. These TICs
role in modulating calcium oscillation amplitude, which may b
also suggested that a2d1 could serve as a therapeutic target i
TICs and could potentially be developed into an anti-HCC dr
recurrence at both the cellular andmolecular levels and advancoften operationally referred to as cancer stem cells or tumor-initi-
ating cells (TICs), behave like stem cells in that they are capable
of self-renewal and of giving rise to a hierarchical organization of
heterogeneous cancer cells. These cells are resistant to conven-
tional chemotherapy and radiotherapy and, hence, are respon-
sible for sustaining tumor growth and recurrence. Therapies
that can eradicate these cells may eventually lead to cancer
cures (Alison et al., 2011; Clarke et al., 2006; Rosen and Jordan,
2009; Visvader and Lindeman, 2012; Zhang et al., 2010).
CD133+, CD13+, CD24+, and EpCAM+ cells, as well as some
side populations from HCC cell lines and/or biopsies, have
been identified as TICs, but their roles in HCC recurrence and
therapeutic strategies to target these cells have only recentlyies and expressing a2d1 in primary HCC and some surgical
have prognostic value. a2d1 was found to play an essential
e important in maintaining the properties of TICs. The study
n the treatment of HCC. Additionally, 1B50-1 bound a2d1 on
ug. These findings contribute to the understanding of HCC
e the development of prognostic and therapeutic strategies.
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a2d1 and Liver Tumor-Initiating Cellsbegun to be investigated (Chiba et al., 2006; Haraguchi et al.,
2010; Lee et al., 2011; Ma et al., 2010; Mishra et al., 2009; Yama-
shita et al., 2009).
Antibody-based targeted cancer therapy, either alone or in
combination with standard chemotherapy regimens, has shown
increasing clinical and commercial success (Deonarain et al.,
2009). The current antibody-based anticancer therapies do not
result in complete remission, but trials using antibodies targeting
the surface molecules of TICs, such as DLL4, CD123, CD133,
and interleukin-4 (IL-4), have shown promising therapeutic
effects in a variety of cancers (Hoey et al., 2009; Jin et al.,
2009; Rappa et al., 2008; Todaro et al., 2007). However, system-
atic identification of TIC biomarkers suitable for targeting anti-
body development is currently hindered by the sparseness of
the TIC population in a given specimen.
We previously established a pair of HCC cell lines with the
same clonal origin, Hep-11 and Hep-12, by primary culture
from the same patient’s primary and recurrent HCC tissues,
respectively. Hep-12 cells are enriched for TICs, whereas Hep-
11 cells do not form tumors in nonobese diabetic/severe
combined immunodeficient (NOD/SCID) mice up to 6 months
after injection of 5 3 106 cells (Xu et al., 2010). These two cell
lines thus provide a unique cellular model system for character-
izing the nature of the cells related to HCC recurrence and for
identifying biomarkers for targeted therapy, specifically against
recurrent HCC and perhaps for TICs in general. In this study,
we used these two cell lines to generate monoclonal antibodies
(mAbs) aiming to identify and target cells specifically related to
HCC recurrence and to investigate the nature of these cells.
RESULTS
1B50-1 Identifies a Highly Tumorigenic and Invasive
Subpopulation of HCC Cells
We used a whole-cell subtractive immunization approach
(Brooks et al., 1993; Rasmussen and Ditzel, 2009) to generate
mAbs that specifically reacted with Hep-12 cells. From three
batches of cell fusions with the spleens of mice immunized
with Hep-12 cells, a total of 37 hybridoma clones secreting
mAbs that reacted strongly with Hep-12 cells, but weakly with
Hep-11 cells, were obtained after screening with a cell-based
ELISA method. One of these antibodies, named 1B50-1, recog-
nized a subset of highly tumorigenic Hep-12 cells and appeared
to be cytotoxic in vivo in our preliminary tumorigenicity assay.Figure 1. Characterization of 1B50-1+ HCC Cells
(A) Immunofluorescence staining for 1B50-1 in HCC cell lines. Nuclei were staine
(B) Representative photograph showing tumor formation in NOD/SCIDmice inject
11 cells.
(C) The histology of the tumors formed by 1B50-1+ cells was compared with tha
(D) Sorted 1B50-1+ and 1B50-1 cells were assayed for their invasive ability on M
independent experiments. *Student’s t test.
(E) Flow cytometry results showing the percentage of 1B50-1+ cells in parental
serum-containing medium for 2 weeks (Cultured) or transplanted into NOD/SCID
(F) qRT-PCR analysis of the expression of stem cell markers and drug-resistance-
fold difference over 1B50-1 cells for each gene, which was defined as 1 (calibr
(G) Representative flow cytometry results from analyzing indicated markers. For t
specific inhibitor DEAB were used to set the gate.
(H) Tumorigenic cell frequency in each fraction of Huh7 cells was determined wi
See also Figure S1.1B50-1 bound to an antigen on the Hep-12 cell membrane, while
it recognized few Hep-11 cells (Figure 1A). The percentage of
cells bound by 1B50-1 (1B50-1+) cells varied from 0.5% to less
than 5% across HCC cell lines, with the exception of Hep-12
cells, more than 90% of which were 1B50-1+ (Table 1).
To confirm that 1B50-1+ cells have tumor initiation ability, we
first purified 1B50-1+ and 1B50-1 cells from five HCC cell lines
by fluorescence-activated cell sorting (FACS) and performed
tumorigenicity assays in NOD/SCID mice with limiting dilution.
As shown in Table 1, as few as 100 purified 1B50-1+ cells from
the Huh7, Hep-12, HepG2, and SMMC7721 cell lines initiated
tumor formation in almost all transplanted mice. For the least
tumorigenic Hep-11 cell line, 1,000 purified 1B50-1+ cells also re-
sulted in tumor formation in five of five transplanted mice. The
1B50-1 counterparts either were completely nontumorigenic
or formed tiny nodules only occasionally (Figure 1B; Figure S1A
available online). We then tested the tumorigenic potential of
1B50-1+ and 1B50-1 cells sorted from primary HCC-derived
cells of four HCC patients. Again, 100 or 1,000 1B50-1+ cells
were consistently more tumorigenic than their 1B50-1 counter-
parts (Table 1; Figure S1A). Hematoxylin and eosin (H&E) staining
demonstrated that the histological features of tumors formed by
the 1B50-1+ fractions resembled the tumors from which they
derived, retaining the phenotypic heterogeneity, except those
from Hep-12 cells, whose tumor morphology was slightly
different from the original patient tissue (Figure 1C; Figure S1B).
We also compared the invasive property of 1B50-1+ and
1B50-1 cells on Matrigel with a Boyden chamber assay. As
shown in Figure 1D, 1B50-1+ cells were more invasive than their
1B50-1 counterparts.
Differentiation Properties of 1B50-1+ Cells
We next evaluated the differentiation potential of purified 1B50-
1+ cells from Hep-12 and Huh7 cell lines. After purified 1B50-1+
Huh7 cells were cultured in vitro for 2 weeks, the percentage
of 1B50-1+ cells decreased from 92.33% to 1.23%, a value
similar to that of the parental Huh7 population (Figure 1E).
Furthermore, analysis of single-cell clones from Huh7 cells indi-
cated that 1B50-1+ cells underwent differentiation, giving rise
to both 1B50-1+ and 1B50-1 populations, whereas the
percentage of 1B50-1+ cells in the clones from the 1B50-1 frac-
tion was unchanged (Figures S1C and S1D). It is important to
note that the percentage of 1B50-1+ cells in tumors formed by
purified 1B50-1+ Huh7 cells in NOD/SCID mice also decreasedd by DAPI.
ed s.c. with 1,000 sorted 1B50-1+ (black arrows) and 1B50-1 (red arrows) Hep-
t of the HCC tissues from the original patient by H&E staining.
atrigel using a Boyden chamber assay. Bars represent the mean ± SD of three
cells, FACS-purified 1B50-1+ cells and purified 1B50-1+ cells cultured in 10%
mice (Tumor).
related genes in purified 1B50-1+ and 1B50-1 populations. Data presented as
ator). Error bars indicate SD.
he ALDH assay, cells incubated with Aldefluor substrate BAAA and the ALDH-
th limiting dilution assay in NOD/SCID mice.
Cancer Cell 23, 541–556, April 15, 2013 ª2013 Elsevier Inc. 543
Table 1. Tumorigenicity of 1B50-1+ and 1B50-1– Cells Sorted from HCC Cell Lines and Clinical Specimen-Derived Cells in NOD/SCID
Mice
Cells
Percentage of Positive Cells Positive in 1B50-1+ Cells (%)
Tumor Formation (Tumor Formed/Mice Injected)
1B50-1 Positive 1B50-1 Negative
1B50-1a CD133 CD13 EpCAM CD133 CD13 EpCAM 103 102 103 102
Huh7 0.9–2.2 24.7 37.1 86.1 85.7 75 94.7 5/5(3.8 ± 1.9)b 5/5 3/5(0.09 ± 0.06)b 0/5
Hep-11 0.4–0.7 91.2 97.4 99.9 100 100 97.8 5/5 1/5 0/5 0/5
Hep-12 92.1–94.8 76.3 97.1 99.7 78.5 98.4 99.9 5/5(4.5 ± 1.1)b 5/5 3/5(1.3 ± 0.3)b 0/5
HepG2 0.5–2.1 4.2 53.4 4.8 85.5 94.3 85.7 4/5 4/5 0/5 0/5
SMMC7721 0.5–0.6 4.8 23.2 3.6 94.3 86 85.1 5/5 5/5 0/5 0/5
Case-1c 1.7–3.3 2.4 30.3 28.8 84.3 92.1 97.6 5/5(3.5 ± 1.0)b 5/5 3/5(0.12 ± 0.04)b 0/5
Case-2c 0.6–2.1 2.1 87.7 2.5 90.3 97.6 78.7 3/5 2/5 0/5 0/5
Case-3c 0.4–1.8 1.5 85.5 15.8 96.8 91.7 95.2 5/5(1.3 ± 0.6)b 3/5 5/5(0.6 ± 0.4)b 1/5
Case-4c 0.6–1.3 8.6 13.7 4.1 89.8 93.7 91.8 2/5 0/5 0/5 0/5
aThe results of two to eight flow cytometry analyses.
bThe data in the parentheses are the average volume ± SD of tumors formed (cm3).
cHCC specimens were undergone primary culture and expanded in vitro for less than ten passages.
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able to differentiate into 1B50-1 cells but not vice versa.
However, purified 1B50-1+ Hep-12 cells retained their high
percentage of 1B50-1+ cells whether they were kept in culture
or in vivo, like the parental Hep-12 cells (Figure 1E; Figure S1E).
1B50-1+ Cells Express Multiple Stem Cell Genes
To confirm that 1B50-1+ cells represent cells with stem cell-like
properties at the molecular level, the expression of a panel of
genes associated with liver progenitor cells (Sell and Leffert,
2008) was compared between 1B50-1+ and 1B50-1 popula-
tions purified fromHep-12 andHuh7 cells by quantitative reverse
transcription (qRT)-PCR (Figure 1F). Compared with 1B50-1
cells, 1B50-1+ cells from both cell lines consistently expressed
higher levels of OCT4, SOX2, NANOG, BMI1, AFP, and CTNNB.
Furthermore, the expression of the drug efflux transporter gene
ABCG2 and the multidrug resistance gene MDR1 was elevated
in the 1B50-1+ fractions.
It is interesting that 1B50-1+ cells overlapped with CD133+,
EpCAM+, CD13+, and ALDH+ populations of Hep-12 cells (Fig-
ure 1G). Although themajority of 1B50-1+ cells were also positive
for CD133, EpCAM, CD13, and ALDH in Huh7 cells, only a small
fraction of CD133+, EpCAM+, CD13+, or ALDH+ cells were 1B50-
1+ (Figure 1G). A similar correlation between 1B50-1 and these
reported HCCTICmarkers was also found in other HCC cell lines
and patient-derived cells (Table 1). Thus, 1B50-1+ cells represent
fractions of CD133+, EpCAM+, and CD13+ populations but not
vice versa.
1B50-1+ Cells Are a More Restricted Subset of Highly
Tumorigenic Cells among CD13+, CD133+, and EpCAM+
HCC TIC Populations
The relationship of 1B50-1 to the other liver TIC markers CD13,
CD133, and EpCAM and the fact that the 1B50-1+ fraction of
nontumorigenic Hep-11 cells, which were more than 91% posi-
tive for CD13, CD133, and EpCAM, was tumorigenic led us to
propose that the previously reported HCC TIC population
defined by CD13+, CD133+, or EpCAM+ might be mainly attrib-544 Cancer Cell 23, 541–556, April 15, 2013 ª2013 Elsevier Inc.uted to the existence of their respective 1B50-1+ subsets. To
confirm this, we compared the tumor-forming ability of different
fractions of Huh7 cells (Figure 1H). As few as 100 cells of
1B50-1+CD13+, 1B50-1+CD133+, and 1B50-1+EpCAM+ subsets
formed tumors in almost all the transplanted mice, whereas
only small nodules were occasionally found in all other frac-
tions that were 1B50-1. Cells only positive for CD13, CD133,
or EpCAM did not have significantly higher tumor formation
ability compared with each corresponding double-negative
fraction.
Clinical Significance of 1B50-1+ Cells in HCC and
Surgical Margin Tissues
Because 1B50-1 did not stain formalin-fixed tissues, we exam-
ined its staining by fluorescence immunohistochemistry using
86 paired frozen HCC and paracancerous tissues that were ob-
tained from the hepatectomymargins, six recurrent HCC tissues,
and five normal liver samples from hepatic hemangioma
patients. As shown in Figure 2A, 1B50-1 reacted with an antigen
on the cell surface in the positive tissues and 1B50-1+ cells
showed a scattered distribution in 72.1% of HCC tissues,
whereas they were detected in only 46.5% of paracancerous
tissues (Table S1). Furthermore, 1B50-1+ staining in paracancer-
ous tissues was only found in those patients with positive stain-
ing in their tumor tissues. No 1B50-1+ cells were observed in the
five normal liver tissues. It is important to note that 1B50-1+ cells
were enriched in the recurrent HCC tissues of four patients out of
six tested.
Next, we examined the tumorigenic capability of 1B50-1+ and
1B50-1 cells sorted directly from freshly resectedHCCand par-
acancerous tissues of three patients (Figure 2B). 1B50-1+ cells
isolated from the tumor tissues of all three patients gave rise to
tumor growth after transplantation of as few as 1,000 cells, while
those purified from the paracancerous tissues in two out of three
patients also initiated tumor growth within 8 weeks after trans-
plantation. As many as 105 1B50-1 cells isolated from either
tumor or paracancerous tissues caused no visible tumor forma-
tion after 4 months. H&E staining showed no difference in the
Cancer Cell
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tissues, which both resembled that of the tumor tissue of the
patient (Figure 2C).
Finally, we analyzed the correlation between the clinicopatho-
logic characteristics and 1B50-1 staining status (Table S1). No
significant correlation was found between the 1B50-1+ staining
in HCC tissues and any clinicopathologic factor. However, the
presence of 1B50-1+ cells in the paracancerous tissues did
correlate significantly with hepatic cirrhosis, very rapid recur-
rence, and a lower rate of 4-year overall survival postsurgery.
Kaplan-Meier curves revealed that the 1B50-1 staining status
in the tumor tissues did not correlate with disease-free or overall
survival of these patients, but the median disease-free survival
and the 75th percentile overall survival time postsurgery in the
patients with 1B50-1 staining in the paracancerous tissues
were approximately 4.5 and 10.1 times, respectively, those
with positive staining (Figures 2D–2G). Multivariant Cox regres-
sion analysis also showed that 1B50-1+ staining in HCC
paracancerous tissues was an independent risk factor of poor
prognosis for HCC patients (Figure 2H).
Self-Renewal Property of 1B50-1+ Cells
To further confirm that 1B50-1+ cells have stem cell-like proper-
ties, we first performed sphere formation assays to determine
their in vitro self-renewal ability. 1B50-1+ cells purified from
various HCC cell lines and clinical specimens displayed signifi-
cantly higher sphere-forming efficiency compared with their
respective 1B50-1 counterparts. Furthermore, the sphere-
forming ability of 1B50-1+ cells expanded in subsequent serial
propagations (Figures 3A and 3B). We then performed in vivo
serial transplantation assays with resorted cells from tumors
formed by 1B50-1+ cells. Once again, 1B50-1+ cells formed
tumors in the second transplanted mice, while their 1B50-1
counterparts remained nontumorigenic (Figure 3C). These
results demonstrate that 1B50-1+ cells have self-renewal ability
both in vitro and in vivo.
In Vitro Effects of 1B50-1 on HCC Cells
To evaluate if 1B50-1 could have some effects on liver TICs, we
first tested the sphere-forming ability of 1B50-1+ cells following
1B50-1 treatment. As shown in Figure 3D, 1B50-1 at 10 mg/ml
significantly suppressed the sphere formation of 1B50-1+ cells
purified from all HCC cell lines and patient-derived specimens
tested.
We then examined the effect of 1B50-1 on the apoptosis of
1B50-1+ cells by a terminal deoxynucleotidyl transferase dUTP
nick-end labeling (TUNEL) assay. 1B50-1 induced apoptosis of
the cultured Hep-12 cells in a dose-dependent manner. The
apoptosis-inducing effect was also confirmed in 1B50-1+ frac-
tions purified from other cell lines. No significant cell apoptosis
was observed for unpurified Hep-11 cells upon 1B50-1 treat-
ment (Figures 3E and 3F; Figure S2).
Finally, we treated cultured HCC cells with 1B50-1 at 10 mg/ml
for 48 hr, followed by transplanting the cells into NOD/SCIDmice
subcutaneously (s.c.) with limiting dilution. While 106 cells of
control groups (treated with immunoglobulin G [IgG]) formed
tumors in all the transplanted mice within 3–4 weeks after injec-
tion, none of the mice transplanted with 1B50-1-treated cells
showed tumor formation after 12 weeks (Figure 3G). Thesedata indicate that tumorigenic cells are eradicated by ex vivo
1B50-1 treatment.
1B50-1 Suppresses the Growth of HCC In Vivo and
Eradicates TICs
Next, we examined whether 1B50-1 could have a therapeutic
effect on established HCC engraftments by administering
1B50-1 intraperitoneally (i.p.). As shown in Figures 4A–4C, the
growth of both Hep-12 and Huh7 cells was dramatically sup-
pressed by 1B50-1 treatment in a dose-dependent manner,
although the percentages of positive cells varied greatly
between the two cell lines (Table 1). Some of the tumors formed
by Hep-12 cells almost completely disappeared following 1B50-
1 treatment. The suppression effect of 1B50-1was also detected
on xenografts derived from a HCC primary culture (Figure 4D).
Because 1B50-1 treatment alone retarded tumor growth only
to a moderate degree, we examined the therapeutic efficacy of
the combination of 1B50-1 and doxorubicin (DXR). By injecting
800 mg 1B50-1 and 1.5 mg/kg DXR i.p. per mouse, the growth
of Huh7 engraftments was inhibited by as much as 89.0%
compared with the control, representing a further 46.5% inhibi-
tion compared with DXR alone (Figures 4E and 4F). A similar
effect with combined therapy was also observed for tumor xeno-
grafts directly derived from two HCC patients (patient-derived
xenograft [PDX]) (Figures 4G and 4H). The survival of mice was
also improved following combined therapy in the PDX models
(Figures 4I and 4J).
We then analyzed the TICs in the residues of treated Huh7
engraftments. Although the tumor inhibition of 1B50-1 was less
effective than DXR, the proportion of 1B50-1+ cells decreased
upon antibody treatment, whereas the population of 1B50-1+
cells was significantly enriched after DXR treatment (Figure 4K).
Moreover, serial transplantation of 104 cells into secondary
NOD/SCID mice from tumors that received 1B50-1 treatment
formed tumors in two out of 10 mice, while the cells from the
control and DXR-treated tumors subsequently formed tumors
in nine out of 10 and five out of five injected mice, respectively,
with DXR-treated cells developing tumors more rapidly. Notably,
only a tiny nodule was found in one out of five mice transplanted
with residual cells from an engraftment treated with 1B50-1 plus
DXR (Figures 4L and 4M), suggesting TICs were reduced
following combined treatment in vivo.
We next detected apoptotic cells by TUNEL assay in the xeno-
grafts following 1B50-1 treatment. Consistent with in vitro
results, the apoptotic cell percentage increased significantly in
both Hep-12 and HuH7 engraftments treated with 800 mg
1B50-1 per mouse (Figures 4N and 4O; Figure S3).
These data demonstrate that 1B50-1 has a therapeutic effect
on HCC by targeting TICs, which is augmented by combination
with DXR.
The Antigen Recognized by 1B50-1 Is a2d1, Isoform 5
To identify the antigen recognized by 1B50-1, we performed
immunoprecipitation and mass spectrometry analysis using
Hep-11 and Hep-12 cells. Unlike in Hep-11 cells, immunopre-
cipitation of Hep-12 cell lysates with 1B50-1 resulted in several
dominant bands observed by SDS-PAGE (Figure 5A). Only the
150 kDa band was predicted to be a membrane protein
with a matched molecular weight of glycosylated a2d1,Cancer Cell 23, 541–556, April 15, 2013 ª2013 Elsevier Inc. 545
Figure 2. Clinical Significance of 1B50-1+ Cells in HCC Patients
(A) Immunohistochemical staining of cryostat sections of primary and recurrent HCC tissues, paracancerous tissues and normal liver with 1B50-1. Nuclei were
stained with DAPI. Arrows indicate positive cells.
(B) The tumorigenicity of 1B50-1+ and 1B50-1 cells purified directly from freshly resected HCC andmatched paracancerous tissues. #The data are expressed as
number of tumors formed/number of sites injected, and the numbers of cell injected are shown in parentheses.
(C) H&E staining of the tumors formed in (B) by 1B50-1+ cells from both the tumor and paracancerous tissues, as well as the original patient HCC tissue (case-5).
(D–G) Kaplan-Meier curves for disease-free (DFS) and overall survival (OS) were compared according to 1B50-1 staining status in HCC tissues (D and F) and the
paracancerous tissues (E and G).
(legend continued on next page)
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Figure 3. The Self-Renewal Property of 1B50-1+ HCC Cells and the Effects of 1B50-1 In Vitro
(A) Representative phase contrast micrographs show the spheroids formed by 1B50-1+ and 1B50-1 HCC cells.
(B) Histograms showing the spheroid forming efficiency of FACS-sorted 1B50-1+ and 1B50-1 fractions from indicated sources. The ability of the spheres formed
by 1B50-1+ cells to form secondary spheroid was also shown (1B50-1+/2nd). One hundred cells per well were plated (n = 6). Spheroids (R100 mm) were counted
under a stereomicroscope.
(C) Tumor formation of serial transplantation assay: 1B50-1+ and 1B50-1 subsets sorted from xenografted tumors by 1B50-1+ cells in Table 1 and Figure 2Bwere
transplanted s.c. into secondary NOD/SCID mice. #The tumor formed by paracancerous 1B50-1+ cells were used.
(D) Histograms showing the effect of 1B50-1 (10 mg/ml) on spheroid formation of sorted 1B50-1+ cells (n = 6).
(E and F) Histograms showing the effect of 1B50-1 on apoptosis of Hep-11 and Hep-12 cell lines (E) or purified 1B50-1+ subsets from indicated HCC cell lines (F).
Cells were treated with 10 mg/ml 1B50-1 for 48 hr in vitro and processed using TUNEL assay followed by flow cytometry.
(G) The tumorigenicity of HCC cells treated with 10 mg/ml 1B50-1 or nonrelated IgG (control) for 48 hr in vitro and subsequently transplanted into NOD/SCIDmice.
All error bars indicate SD. *Student’s t test. ND, not done.
See also Figure S2.
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(Figures S4A and S4B). Hence, it was selected for further
analysis.(H) Univariate andmultivariate analysis predicts risk factors of poor survival for HC
of at least one 1B50-1+ cell in a whole cryostat slice, which was screened under a
staining indicates that no 1B50-1+ cells were found. Ca, cancer; PCa, paracance
See also Table S1.An analysis of a2d1, which is encoded by CACNA2D1, was
conducted to examine whether its expression was associated
with 1B50-1 staining. qRT-PCR showed that the a2d1 mRNAC patients. *Chi-square test. Note: 1B50-1+ staining is defined as the presence
microscope with a 103 lens blindly by two experienced researchers. Negative
r; RR, relative risk.
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Figure 4. The Therapeutic Effects of 1B50-1 on Established HCC Engraftments in NOD/SCID Mice
(A–D) The mice transplanted s.c. with Hep-12 (A and B, n = 7), Huh7 (C, n = 5), and primary HCC cells (D, n = 5) were injected i.p. with PBS, nonrelated IgG, or
1B50-1 at indicated doses every other day for a total of seven times after the tumors were visible. Tumors were dissected and weighed at experiment termination.
(E and F) Growth curves of Huh7 engraftments treated with 800 mg 1B50-1, 1.5 mg/kg doxorubicin (DXR), or the combination of both, per mouse as indicated by
arrows in (E). The histogram in (F) shows the average weight of the dissected tumors (n = 7).
(G and H) Growth curves of two HCC PDX tumors injected i.p. with 800 mg 1B50-1, 1.5 mg/kg DXR, or the combination of both, per mouse as indicated by
arrows (n = 6).
(I and J) Kaplan-Meier survival curves of the PDX models in (G) and (H) following the treatments.
(legend continued on next page)
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cells (Figure 5B) and in 1B50-1+ subsets compared with their
1B50-1 counterparts from HCC cell lines and primary tumor-
derived cells (Figure 5C). Furthermore, western blot with
a commercial a2d1 mAb showed that Hep-12 cells and 1B50-
1+ HCC specimens expressed high levels of a2d1 protein, while
it was undetectable in Hep-11 cells and IB50-1 paracancerous
tissues (Figures 5D and 5E). Additionally, double staining of Hep-
12 cells and HCC specimens with 1B50-1 and a rabbit polyclonal
a2d1 antibody confirmed that both antibodies colocalized
(Figure 5F).
Because a2d1 has five isoforms, we determined if 1B50-1 is
isoform specific. Double staining (with MYC and 1B50-1
antibodies) of COS-7 cells transiently transfected with each
MYC-tagged a2d1 isoform revealed that 1B50-1 specifically
recognized isoform 5, while it weakly cross-reacted with the
other four isoforms (Figure 5G). Further PCR cloning and
sequencing verified that the mRNA encoding the target protein
in 1B50-1+ HCC cells was indeed that of a2d1 isoform 5 (Figures
S4C and S4D). Consistently, skeletal muscle, which expresses
isoform 1 of a2d1, was positively stained by the commercial
polyclonal a2d1 antibody but was negative for 1B50-1 staining
(Figure 5F), further suggesting that 1B50-1 specifically recog-
nizes isoform 5 of a2d1. Finally, knockdown with shRNAs specif-
ically targeting a2d1 resulted in decreased 1B50-1 staining in
Hep-12 cells (Figures 5H–5J). All of these data confirm that the
antigen recognized by 1B50-1 is indeed isoform 5 of a2d1.
The Effects of a2d1 Knockdown and Overexpression on
TIC Properties
If 1B50-1 functions by blocking a2d1, knockdown of its expres-
sion should mimic the effects of 1B50-1 treatment. To validate
this hypothesis, we performed RNAi experiments. Knockdown
of a2d1 led to reduced sphere formation, enhanced apoptosis,
and decrease of tumorigenic cells among Hep-12 cells (Figures
5K–5M; Figure S4E). In addition, knockdown of a2d1 in purified
1B50-1+ cells from other HCC cell lines and primary HCC-
derived cells reduced sphere formation and tumorigenicity and
increased cell apoptosis (Figures 5K, 5L, and 5N).
We also overexpressed a2d1 isoform 5 in Hep-11 cells and
1B50-1 populations purified from other HCC cell lines. Although
overexpression of a2d1 did not lead to a significant change in
tumorigenicity of Hep-11 cells, it increased hepatosphere-form-
ing efficiency. Similar results were obtained in other 1B50-1
populations upon a2d1 overexpression (Figure 5O).
a2d1 Regulates Calcium Influx in Liver TICs
To determine whether 1B50-1 binding of a2d1, which is a subunit
of a voltage-dependent calcium channel, affects calcium
influx, we first measured changes in intracellular calcium
concentration ([Ca2+]i) with the Ca
2+ indicator Fluo-4AM. [Ca2+]i(K) Residual tumors of (E) were digested into single cells, stained by 1B50-1 a
percentage of 1B50-1+ cells in the residual tumors after treatment.
(L andM) The tumor-initiating ability of the Huh7 engraftment residues after each d
SCID mouse. The data in (M) are from two independent experiments, and the ph
(N and O) Apoptotic cells in engraftments treated with 800 mg 1B50-1 per mousew
by the ratio of TUNEL-positive cells/total number of cells from six randomly sele
See also Figure S3.in Hep-12 cells was significantly higher than that of nontumori-
genic Hep-11 cells, as shown by the intensity of fluorescence.
Treatment of Hep-12 cells with 10 mg/ml 1B50-1 for 24 hr re-
sulted in a 25.5% decrease of fluorescence intensity, which
was statistically significant compared with IgG-treated cells,
whereas Hep-11 cells were not affected by 1B50-1 treatment
(Figure 6A). Furthermore, analysis of [Ca2+]i in other HCC cell
lines and primary HCC-derived cells revealed that the average
[Ca2+]i level in 1B50-1
+ fractions was significantly higher than
that of 1B50-1 subsets, and 1B50-1 treatment resulted in
a marked reduction of [Ca2+]i in 1B50-1
+ cells (Figure 6B; Fig-
ure S5A). Overexpression of a2d1 resulted in elevation of
[Ca2+]i in Hep-11 cells (Figure 6C; Figure S5B), whereas knock-
down of a2d1 in Hep-12 cells led to decrease in [Ca2+]i (Fig-
ure 6D). All these data show that a2d1 plays a role in the calcium
influx in 1B50-1+ liver TICs.
Next, we monitored time-dependent changes in [Ca2+]i in indi-
vidual cells. Irregular calcium transients were observed in most
Hep-12 cells. They appeared more frequently and with more
varied intervals in Hep-12 cells compared with Hep-11 cells, in
which transients were only observed in approximately 1%–2%
of cells (Figures 6E–6G). Calcium transients diminished when
extracellular Ca2+ was chelated with EGTA and restored when
calcium was added into the culture medium (Figures S5C and
S5D), suggesting that spontaneous [Ca2+]i oscillations in TIC-en-
riched Hep-12 cells depended on the influx of extracellular
calcium. Treatment of Hep-12 cells with 1B50-1 did not alter
the frequency of spontaneous [Ca2+]i oscillations, but their
amplitude was significantly suppressed (Figures 6H–6J). a2d1
knockdown in Hep-12 cells gave similar results (Figures 6K
and 6L). These data confirm that a2d1 plays an essential role in
calcium oscillations in HCC TICs and that 1B50-1 inhibits the
function of a2d1.
TheHepatosphere-FormingAbility of 1B50-1+ Liver TICs
Depends on L- and N-type Calcium Channels
Given that a2d1 may function through both calcium channel-
dependent and independent mechanisms and that multiple
calcium channels may be involved in calcium influx, we first
determined which calcium channel is involved in the TIC self-
renewal regulated by a2d1 using specific calcium channel
blockers. As shown in Figure 6M, the hepatosphere formation
ability of 1B50-1+ liver TICs isolated from different HCC cell lines,
as well as that of a2d1-overexpressing Hep-11 cells, was in-
hibited by L-type and N-type but not T-type calcium channel
blockers, indicating that a2d1 regulates TIC self-renewal through
at least L-type and N-type calcium channels.
We then determined whether other subunits of functional
voltage-gated calcium channels were present in the TICs by per-
forming RT-PCR analysis of the mRNAs coding for all known 10
a1 subunits and three b subunits of voltage-gated calciumfter depleting red blood cells, and analyzed by flow cytometry to detect the
rug treatment was assayed by retransplanting 104 cells withMatrigel into NOD/
otograph in (L) shows the dissected tumors of one experiment. ND, not done.
ere detected in situ using the TUNEL assay. The apoptotic index was assessed
cted high-power fields (4003). All error bars indicate SD. *Student’s t test.
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Figure 5. The Roles of a2d1 in HCC TICs
(A) SDS-PAGE analysis of 1B50-1 immunoprecipitation products from Hep-11 and Hep-12 cells. The arrowhead indicates the band that was cut out for mass
spectrometry analysis.
(B) qRT-PCR analysis of the a2d1 mRNA level relative to GAPDH mRNA level in Hep-11 and Hep-12 cell lines.
(legend continued on next page)
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a1C, and a1F subunits were highly expressed in Hep-12 cells
compared with Hep-11 cells, while those for a1A, a1D, a1G,
a1H, b1, and b3 subunits were equally expressed in both cell
lines. Furthermore, when a2d1 was transfected into Hep-11
cells, the expression of a1B, a1C, and a1F mRNAs was induced.
The data were further confirmed with qRT-PCR analysis of a1B,
a1C, a1D, and a1FmRNAs in these cells and sorted 1B50-1+ and
1B50-1 subsets (Figure 6N). These data suggest that the most
important subunits of a functional calcium channel do exist in
TICs and that a2d1 could upregulate the expression of a1B,
a1C, and a1F subunits.
a2d1 Knockdown Inhibits ERK1/2 Phosphorylation and
Triggers Apoptosis
Because calcium oscillations play a pivotal role in activating
signaling cascades that regulate gene transcription and various
cell functions, we performed western blots to investigate the
molecular mechanisms underlying the effects of 1B50-1 treat-
ment and a2d1 knockdown. As shown in Figure 7A, the phos-
phorylation of ERK1/2 in Hep-12 cells was suppressed upon
1B50-1 treatment and a2d1 knockdown, while both the overall
protein and phosphorylation levels of PI3K and AKT were unaf-
fected. Furthermore, consistent with its apoptosis-inducing
effects, both 1B50-1 treatment and a2d1 shRNA knockdown re-
sulted in downregulation of the antiapoptotic protein BCL2 and
upregulation of BAX and BAD, as well as activation of caspases
3, 8, and 9, as shown by increased levels of cleaved proteins.
Notably, the expression of ABCG2 and BMI1, which is important
for stem cell self-renewal (Chiba et al., 2008), was also
downregulated.
Next, we validated the aforementioned data in cells purified
from primary HCC-derived cells by western blot analysis of
some representative proteins. Compared with their 1B50-1
counterparts, 1B50-1+ cells expressed higher levels of ABCG2,
BMI1, BCL2, and OCT4, as well as phosphorylated ERK1/2
(p-ERK1/2). 1B50-1 treatment of 1B50-1+ cells resulted in down-
regulation of these proteins and dephosphorylation of ERK1/2
(Figure 7B).
It is important to note that the expression of those proteins
downregulated by a2d1 blocking, such as BMI1, OCT4,(C) qRT-PCR analysis of the a2d1 mRNA level in purified 1B50-1+ fractions relat
(D and E) Western blot analysis with a a2d1 mAb in HCC cell lines (D) or paired tum
1B50-1 immunofluorescence staining status (1B50-1 IF) is also given above eac
(F) Cultured Hep-12 cells, cryostat sections of HCC tissue and skeletal muscle wer
antibody, and observed under a confocal microscope. The HCC tissue and the s
(G) Immunofluorescent staining of COS-7 cells transiently transfected with indic
fixation.
(H and I) a2d1 mRNA (H) and protein (I) levels of Hep-12 cells stably infected with
(J) Hep-12 cells stably infected with indicated lentivirus were immunostained by
(K) Histogram showing the sphere-forming ability of purified 1B50-1+ subsets
lentivirus for 4 hr, and were plated at 100 cells per well (n = 6).
(L) Sorted 1B50-1+ cells were infected with indicated lentivirus and cultured in ser
analysis of TUNEL-stained cells.
(M) Hep-12 cells stably infected with indicated lentivirus were transplanted s.c. i
(N) The tumorigenicity of 1B50-1+ cells purified from indicated sources after a2d1
4 hr, and 1,000 cells per mouse were injected.
(O) The sphere-forming ability of sorted 1B50-1 cells infected with a2d1 (isofo
*Student’s t test. ND, not done.
See also Figure S4.ABCG2, BCL2, and p-ERK1/2, was upregulated upon a2d1 over-
expression (Figure 7C).
An ERK1/2 Inhibitor, U0126, Mimics the Effects of a2d1
Blocking
The aforementioned findings indicate that the MAPK pathway
regulates liver TIC properties. To test this hypothesis, we treated
Hep-12 cells and 1B50-1+ fractions from other HCC cell lines
with an ERK1/2 inhibitor, U0126. The expression of BMI1,
OCT4, ABCG2, and BCL2 were downregulated by 10 mM
U0126 treatment for 48 hr (Figure 7D). The hepatosphere forma-
tion of Hep-12 cells, purified 1B50-1+ subsets from various HCC
cell lines, and a2d1-overexpressing Hep-11 cells was also sup-
pressed upon U0126 treatment (Figures 7E and 7F). These
data suggest that ERK1/2 inhibition mimics the effects of
1B50-1 treatment and a2d1 knockdown, suggesting that
ERK1/2 activity is essential for the maintenance of HCC TIC
properties.
DISCUSSION
The TICs are proposed to be responsible for tumor recurrence
according to the cancer stem cell hypothesis (Visvader and Lin-
deman, 2012). Here, we identified a population of HCC TIC
expressing a2d1 in primary HCC and some surgical margins
using a mAb, 1B50-1, generated against the recurrent HCC-
derived cell line Hep-12, suggesting these a2d1+ TICs might be
the cell of origin for HCC recurrence.
The differentiation capability of 1B50-1+ cells from the recur-
rent HCC-originated Hep-12 cells, which have a block of differ-
entiation capacity in vitro or in vivo (Xu et al., 2010), is quite
different from those purified from primary HCC-derived cells in
that they established equilibrium at a different percentage of
1B50-1+ cells. This observation indicates that, during tumor
progression, the same TIC population undergoes clonal evolu-
tion under selection pressures that enable these cells to acquire
additional characteristics and to remain in a more stable state.
a2d1 was previously proposed as a potential hepatic progen-
itor cell marker (Yovchev et al., 2007). We confirmed that 1B50-1
recognized many cells in resected mouse liver as well as in
colony-forming units of normal mouse liver (data not shown).ive to that in their 1B50-1 counterparts of indicated sources.
or (T) and paracancerous (N) tissues from HCC patients (E). The corresponding
h lane for comparison. +, positive; , negative.
e fixed withmethanol, double-stainedwith 1B50-1 and a rabbit polyclonal a2d1
keletal muscle were also counterstained with DAPI.
ated MYC-tagged isoform of a2d1 with MYC and 1B50-1 antibodies without
lentivirus harboring scramble (control) or shRNA1 or shRNA2 targeting a2d1.
1B50-1.
after a2d1 knockdown. Sorted 1B50-1+ cells were incubated with indicated
um-free medium for 72 hr, and apoptotic cells were detected by flow cytometry
n NOD/SCID mice at indicated numbers to assay their tumorigenicity.
shRNA knockdown. 1B50-1+ cells were incubated with indicated lentivirus for
rm 5) lentivirus (100 cells per well plated, n = 6). All error bars indicate SD.
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Figure 6. Characterization of Calcium Influx in 1B50-1+ TICs
(A) [Ca2+]i levels in Hep-11 and Hep-12 cells after treated with IgG or 1B50-1 at 10 mg/ml for 24 hr measured by the fluorescence intensity using confocal
microscopy after cells were loaded with Fluo-4AM.
(B) [Ca2+]i levels in 1B50-1
+ and their 1B50-1 counterparts, as well as in 1B50-1+ subsets treated with IgG or 1B50-1 at 10 mg/ml for 24 hr measured by flow
cytometry.
(legend continued on next page)
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correlation with normal liver progenitors. Furthermore, our
inability to find cells reacted with 1B50-1 in normal human liver
specimens is consistent with the notion that liver progenitors
are rare and are not readily detectable in human normal adult
liver (Darwiche and Petersen, 2010). Finally, the finding that the
cells detected by 1B50-1 in paracancerous tissues also have
TIC properties may explain why those patients who have under-
gone hepatectomy still relapse, and this could have prognostic
value. This finding also indicates that specific therapeutic strat-
egies to eradicate these cells should be used for HCC patients
with a2d1+ cells at the surgical margins.
Our data demonstrate that 1B50-1 has a therapeutic effect on
HCC by targeting TICs. Of course, ideally, tumors will disappear
when TICs are disrupted completely, according to the TIC
hypothesis. However, it is difficult to obtain complete pharmaco-
kinetic control, especially in vivo (as shown by this study and
many others; Haraguchi et al., 2010; Visvader and Lindeman,
2012), with an antibody alone, most likely because of inefficient
penetration of the antibody to the cells inside the tumor mass
and because of the presence of other transit-amplifying tumori-
genic cells. Instead, combination therapy of 1B50-1 with other
anti-HCC drugs such as DXR, which most likely disrupt TICs
and fast-proliferating non-TICs, respectively, would be required
to achieve a drastic regression, as demonstrated here.
The target of 1B50-1 was identified and validated as isoform 5
of a2d1, a subunit of voltage-gated calcium channel complexes
(De Jongh et al., 1990; Eroglu et al., 2009). Currently, little is
known about the expression pattern and specific function of iso-
form 5 of a2d1, although other members of the a2d family have
been extensively investigated. Here, we reveal an essential role
of a2d1 isoform 5 for the modulation of calcium influx and the
maintenance of many HCC TIC properties. In addition, it is unde-
tectable inmost normal tissues, so cytotoxicity unlikely would be
a concern. Hence, a2d1 isoform 5 could serve as a therapeutic
target for the development of drugs against HCC that specifically
eradicate TICs.
Our study identified the roles of a2d1 isoform 5 in liver TICs
were related to its calcium influx regulation function through L-
and N-type voltage-gated calcium channels. However, the acti-
vation of voltage-dependent calcium channels is regulated by
polarization and depolarization of membranes, which are often
caused by influx of cations. Polarization/depolarization-related
signaling pathways and some other calcium channels, such as(C) [Ca2+]i levels in Hep-11 cells after a2d1 overexpression measured by flow cy
(D) [Ca2+]i levels in Hep-12 cells following a2d1 knockdown measured by confoc
(E–G) Representative recordings of the fluorescence of individual cells plotted as a
Hep-12 cells (F). A representative type of [Ca2+]i oscillation for a minor Hep-11 p
(H) A representative recording of [Ca2+]i change with time in Hep-12 cells treated
(I) The frequency of [Ca2+]i oscillations in indicated cells treated with IgG or 1B50
(J) The effect of 1B50-1 treatment (10 mg/ml for 24 hr) on the amplitude of [Ca2+]
(K and L) [Ca2+]i oscillation frequency (K) and amplitudes (L) in Hep-12 cells after
(M) The effects of specific calcium channel blockers on spheroid formation wer
overexpressing Hep-11 cells (100 cells per well plated, n = 6).
(N) qRT-PCR analysis of the mRNAs encoding some a1 calcium channel subunit
subsets was calculated over the level of each gene in Hep-11, Hep-11/Vector, an
through (L) are the mean of 40 cells for each group of four independent experim
*, #, and @, Student’s t test; #p < 0.05, and @p > 0.05 versus 0.1% DMSO.
See also Figure S5.nicotinic acetylcholine receptors, are also found to be related
to tumorigenesis (Hung et al., 2008; Lee et al., 2010). It would
be interesting to determine if these molecules are also highly ex-
pressed in a2d1+ liver TICs and, if so, what the roles are of these
molecules in the maintenance of TIC properties.
We identified p-ERK1/2 as a key downstream target of a2d1
function in liver TICs. This finding is consistent with a previous
report that signaling to the nucleus by an L-type calcium channel
is transduced through the MAPK pathway (Dolmetsch et al.,
2001). Because other signaling pathways, such as the nonca-
nonical Wnt pathway, may also be involved in calcium signaling
(MacLeod et al., 2007), further studies are needed to clarify
whether these signaling pathways are also involved in the
maintenance of cancer stem cell-like properties of HCC TICs
by a2d1.
Spontaneous calcium oscillations occur in cells originating
from excitable tissues, such as muscle and neuronal tissues,
but they also occur in embryonic stem cells, mesenchymal
stem cells, immature dendritic cells, and G0/G1-phase cells,
although the regulatory mechanisms and biological functions
have not been elucidated in many cases (Ferreira-Martins
et al., 2009; Kapur et al., 2007; Vukcevic et al., 2010). [Ca2+]i
oscillations, one of the major forms of calcium signaling, can
promote the expression of specific genes, and this is related to
the amplitude and duration of calcium transients, possibly by
keeping transcription factors in the nucleus at high enough levels
to bind enhancer sites and initiate transcription (Dolmetsch et al.,
1997; Dolmetsch et al., 1998; Vukcevic et al., 2010). Here, we
observed that spontaneous [Ca2+]i oscillations were present in
HCC TICs and were controlled by calcium influx. Because
many TIC properties, such as self-renewal, tumorigenicity, and
survival, were affected by 1B50-1 treatment and knockdown of
a2d1 and because these treatments resulted in changes in
gene expression and a strong decrease in the amplitude of
[Ca2+]i oscillations, we propose that a2d1 is involved in ‘‘ampli-
tude-encoding’’ signals that maintain the properties of HCC
TICs and that inhibition of this signaling could serve as a thera-
peutic strategy for HCC.EXPERIMENTAL PROCEDURES
Cell Lines and Clinical Samples
The HCC cell lines Hep-11, Hep-12, HuH7, SMMC-7721, and HepG2 were
cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum,tometry.
al microscopy.
function of time showing the change of [Ca2+]i in the majority of Hep-11 (E) and
opulation was shown in (G).
with 1B50-1 at 10 mg/ml for 24 hr.
-1 at 10 mg/ml for 24 hr.
i oscillations in Hep-12 cells.
a2d1 stable knockdown.
e tested using FACS-purified 1B50-1+ cells from indicated sources or a2d1-
s in indicated cells. The fold difference of Hep-12, Hep-11/a2d1, and 1B50-1+
d 1B50-1 cells, respectively. Error bars in all panels indicate SD. The data in (I)
ents.
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Figure 7. Molecular Mechanisms Underlying the Effects of a2d1 Blocking
(A) Western blot analysis using lysates of Hep-12 cells treated with IgG or 1B50-1 at indicated doses (per ml) for 48 hr or stable pools infected with lentivirus
harboring scramble or shRNA1 or shRNA2 targeting a2d1.
(B) Western blot analysis using lysates of 1B50-1+ (lane 1), 1B50-1 (lane 2), and 1B50-1+ cells treated with 10 mg/ml 1B50-1 for 48 hr (lane 3). 1B50-1 fractions
were sorted from Case-4 HCC-derived cells.
(C) Western blot analysis to detect the change of representative molecules associated with HCC TICs in Hep-11 cells after a2d1 (isoform 5) overexpression.
(D) Western blot results show the expression of HCC TIC-related molecules in Hep-12 cells treated with U0126 for 48 hr.
(E) The sphere-forming ability of Hep-12 cells treated with an ERK1/2 inhibitor, U0126.
(F) The effect of U0126 on the sphere-forming ability of sorted 1B50-1+ cells from indicated sources and a2d1-overexpressing Hep-11 cells. One hundred cells per
well were plated (n = 6). All error bars indicate SD. *Student’s t test.
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a2d1 and Liver Tumor-Initiating Cells100 U/ml penicillin, and 100 mg/ml streptomycin (Invitrogen, Grand Island, NY,
USA) in a humidified atmosphere of 5% CO2 at 37
C.
Primary HCC specimens and matched adjacent normal tissues were
collected and snap-frozen into liquid nitrogen from patients who received
a hepatectomy with written informed consent. Some fresh HCC tissues were
mechanically minced and collagenase IV digested, followed by FACS or
primary culture in RPMI 1640 medium containing 10% fetal bovine serum
and expansion after removal of fibroblasts. The PDX models were established
using mechanically minced fresh HCC specimens. Acquisition and use of
these tissues were approved by the Ethics Committee of Peking University
Cancer Hospital.
Antibody Production
Subtractive immunization was used to generate antibodies recognizing the
epitopes specifically enriched in Hep-12 cells. In brief, mice were immunized
with Hep-11 cells, administered 200 mg/kg cyclophosphamide (Sigma-554 Cancer Cell 23, 541–556, April 15, 2013 ª2013 Elsevier Inc.Aldrich, St. Louis, MO, USA), and boosted three times with Hep-12 cells.
Fusion, hybridoma screening, antibody production, and purification were per-
formed using standard protocols.
Cell Labeling and Flow Cytometry Analysis
For flow cytometry analysis or FACS, cells were dispersed, labeled, and
analyzed as previously described (Xu et al., 2010). 1B50-1 was directly labeled
with PE-Cy5 or fluorescein using the respective Lightning conjugation kits
following the vendor’s protocol (Innova Biosciences Ltd., Cambridge, UK).
Tumorigenicity Assay in NOD/SCID Mice
For the tumorigenicity assay, various numbers of FACS-purified cells were
suspended in 50 ml of a 1:1 mix of plain RPMI 1640 and Matrigel (BD Biosci-
ences, Bedford, MA, USA) and transplanted s.c. into the armpit of 4- to 6-
week-old NOD/SCID mice (Vitalriver, Beijing, China). Tumor formation was
monitored weekly.
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of 4- to 6-week-old NOD/SCID mice (2 3 106 cells per mouse). When all the
tumors were visible, mice with comparably sized tumors were randomly sepa-
rated into control and treatment groups and injected i.p. with PBS, nonrelated
IgG, 1B50-1, or DXR. The tumor volume was determined using the formula V =
L3W23 0.5, where L andW represent the largest and the smallest diameters,
respectively.
All animal experiments were performed in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory Animals with
protocols approved by the Animal Care and Use Committee at Peking Univer-
sity Cancer Hospital.
Immunohistochemistry Staining
Frozen tissues were sectioned with a cryostat and fixed with methanol for 30 s.
After blocking with 5% nonfat milk in PBS, slides were incubated with 1B50-1
mAb alone or combined with a polyclonal antibody against a2d1 (Catalog
#HPA008213, Sigma, St. Louis, MO, USA) at 4C overnight, followed by reac-
tion with fluorescein isothiocyanate (FITC)-goat antimouse IgG or both FITC-
goat antimouse IgG and rhodamine-goat antirabbit IgG. Nuclei were stained
with 4,6-diamidino-2-phenylindole dihydrochloride (DAPI; Polysciences, War-
rington, PA, USA) at 0.5 mg/ml. Specimensweremounted in 90%glycerol/PBS
containing 2.5% 1, 4-diazabicyclo(2,2,2)octane. Slides were examined with
a Leica SP5 confocal microscope (Leica, Wetzlar, Germany).
Sphere Formation Assay
To assay sphere formation efficiency, cells were plated in Ultra Low Attach-
ment 96-well plates (Corning Incorporated Life Sciences, Acton, MA, USA)
and cultured in Dulbecco’s modified Eagle’s medium/F12 (Invitrogen) supple-
mented with B27 (Invitrogen), 20 ng/ml epidermal growth factor, 20 ng/ml
basic fibroblast growth factor (Peprotech), 10 ng/ml hepatocyte growth factor
(Peprotech, Rocky Hill, NJ, USA), and 1%methylcellulose (Sigma). Cells were
incubated in a CO2 incubator for 2–3 weeks, and spheres were counted under
a stereomicroscope (Olympus, Tokyo, Japan).
Intracellular Calcium Measurement
For the confocal laser scanning microscope method, cells were rinsed twice
with warmed Tyrode’s solution (140 mM NaCl, 5.0 mM KCl, 1.0 mM MgCl2,
5.5 mM glucose, 10 mM HEPES, 1.8 mM CaCl2, pH 7.2) and labeled with
Fluo-4/AM in Tyrode’s solution for 15 min at room temperature (RT). After
washing, fluorescence was measured at RT using a Zeiss confocal imaging
system with a 403 water immersion lens (Carl Zeiss, Jena, Germany). A total
of 500 images for each field were captured at intervals of 1.56 s, and the fluo-
rescencewas quantified over all the cells in three to six random fields using Im-
ageJ software (http://rsb.info.nih.gov/ij/). The change in [Ca2+]i was expressed
as DF = (F  F0)/F0, where F = fluorescence intensity and F0 = resting
fluorescence.
For flow cytometry measurement of [Ca2+]i level, trypsin-digested cells were
loaded with Fluo-4/AM as described earlier and analyzed with a flow
cytometer.
Statistical Analysis
Using the SPSS 13.0 software, the significance of differences was determined
with a double-sided Student’s t test or a c2 test unless otherwise specified.
Tumorigenic cell frequency was calculated based on extreme limiting dilution
analysis using the webtool at http://bioinf.wehi.edu.au/software/elda/ (Hu and
Smyth, 2009). p% 0.05 was considered statistically significant.
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